Lexington, KY, United States of America

Michael Aksenov

This inventor holds 1 USPTO granted patent. Top assignee: University of Kentucky Research Foundation. Active years: 1998.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Aksenov: Innovator in Peptide Enhancement

Introduction

Michael Aksenov is a notable inventor based in Lexington, KY (US). He has made significant contributions to the field of biochemistry, particularly in the enhancement of peptide activity. His innovative approach has the potential to impact various applications in medical and pharmaceutical research.

Latest Patents

Aksenov holds a patent for a process titled "Process for enhancing the activity of amyloid .beta. peptides." This novel process involves several steps, including providing an oligopeptide or polypeptide, dissolving it in an organic solvent, heating, removing the solvent, and recovering an oligopeptide or polypeptide with enhanced activity. The patent also discloses novel oligopeptides and polypeptides that are enhanced by this innovative process.

Career Highlights

Michael Aksenov is affiliated with the University of Kentucky Research Foundation, where he conducts his research and development. His work has garnered attention for its potential applications in enhancing peptide activity, which is crucial for various therapeutic interventions.

Collaborations

Aksenov has collaborated with esteemed colleagues, including D Allan Butterfield and John M Carney. These partnerships have contributed to the advancement of his research and the successful development of his patented processes.

Conclusion

Michael Aksenov is a pioneering inventor whose work in peptide enhancement showcases his commitment to advancing biochemistry. His innovative processes and collaborations highlight the importance of research in developing new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…